百奥赛图宣布与育世博达成合作,推进双特异性抗体双药物偶联物(BsAD2C)研发

美国商业资讯
Jan 07, 2025

双方共同启动双特异性抗体双药物偶联物(BsAD2C)项目百奥赛图的RenLite®平台与育世博的AD2C技术结合,打造创新的精准肿瘤治疗方案(美国商业资讯)-- 百奥赛图(HKEX:02315)与育世博(6976.TT)今日正式宣布达成战略合作,启动双特异性抗体双药物偶联物(BsAD2C)的共同开发计划。该合作计划旨在针对肿瘤治疗中最具挑战性的问题—肿瘤异质性与药物抗药性,提供创新性的解决方案。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10